Back to top
more

PRA Health Sciences, Inc. (PRAH)

(Delayed Data from NSDQ)

$93.38 USD

93.38
1,010,066

+1.38 (1.50%)

Updated May 3, 2019 04:00 PM ET

After-Market: $93.43 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Allscripts' (MDRX) Unit Inks Deal to Boost Clinical Research

by Zacks Equity Research

Allscripts' (MDRX) unit, Veradigm, enters into a strategic partnership with PRA Health (PRAH) to expand patients' access to clinical research.

Here's Why You Should Retain PRA Health (PRAH) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about PRA Health (PRAH) owing to its strategic alliances and solid CRO market prospects.

PRA Health's (PRAH) New Solution to Speed Up Drug Development

by Zacks Equity Research

PRA Health's (PRAH) tokenization solution can help in the generation of enhanced evidence for drug development through Synoma.

PRA Health (PRAH) Stock Down 0.3% Despite Q1 Earnings Beat

by Zacks Equity Research

PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the first quarter.

PRA Health Sciences (PRAH) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 0.75% and 9.22%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Sonos, Dollar General, PerkinElmer, PRA Health Sciences and Hologic highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Sonos, Dollar General, PerkinElmer, PRA Health Sciences and Hologic highlighted as Zacks Bull and Bear of the Day

PRA Health Sciences (PRAH) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research

PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Urmimala Biswas headshot

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

by Urmimala Biswas

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

PRA Health Sciences (PRAH) Surges 3.8%: Is This an Indication of Further Gains?

by Zacks Equity Research

PRA Health Sciences (PRAH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

PRA Health (PRAH) Chosen by MedChi to Offer Telehealth Services

by Zacks Equity Research

PRA Health's (PRAH) company, Care Innovations, gets selected by MedChi to provide remote patient monitoring services, thereby enabling better patient care.

Merck KGaA Chooses PRA Health's (PRAH) Remote Monitoring Tool

by Zacks Equity Research

PRA Health's (PRAH) remote patient monitoring platform will enable Merck KGaA to offer patients an array of advanced tools to help manage their conditions.

Ecolab (ECL) Unveils Its Enhanced Smart Water Navigator

by Zacks Equity Research

Ecolab's (ECL) smart tool is expected to bridge the widening gap between freshwater supply and demand via efficient water management.

Why Is PRA Health Sciences (PRAH) Down 0.7% Since Last Earnings Report?

by Zacks Equity Research

PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PRA Health (PRAH) Unveils Toolkit for Rare Disease Patients

by Zacks Equity Research

PRA Health (PRAH) launches patient-focused toolkit to lower the burden on patients with rare diseases to participate in clinical research.

    PRA Health (PRAH) Stock Down 2.8% Despite Q4 Earnings Beat

    by Zacks Equity Research

    PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the fourth quarter.

    Company News for Feb 25, 2021

    by Zacks Equity Research

    Companies In The News Are: VCEL, LNG, HZNP, PRAH

    PRA Health Sciences (PRAH) Beats Q4 Earnings and Revenue Estimates

    by Zacks Equity Research

    PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 5.44% and 5.42%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

    PRA Health Sciences (PRAH) Down 2.5% Since Last Earnings Report: Can It Rebound?

    by Zacks Equity Research

    PRA Health Sciences (PRAH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom

    by Zacks Equity Research

    Zacks Industry Outlook Highlights: Teladoc, PRA Health and DexCom

    Urmimala Biswas headshot

    IoMT Meets New Healthcare Needs: 3 MedTech Trends to Watch

    by Urmimala Biswas

    Medical device which has for long taken tiny steps toward IoMT is now going all out to make the most of the advancements in this space amid the pandemic.

    Improving Patient Volumes Aid Select Medical's (SEM) Prospects

    by Zacks Equity Research

    Recovery in patient volumes owing to relaxation of government-imposed constraints is gradually restoring the patient admissions, thereby reinstating Select Medical (SEM) on the growth path.

    PRA Health (PRAH) Gains 4.3% Following Q3 Earnings Beat

    by Zacks Equity Research

    PRA Health's (PRAH) Data Solutions and Clinical Research segments put up a strong performance in the third quarter.

    PRA Health Sciences (PRAH) Q3 Earnings and Revenues Beat Estimates

    by Zacks Equity Research

    PRA Health Sciences (PRAH) delivered earnings and revenue surprises of 15.04% and 3.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

    Analysts Estimate PRA Health Sciences (PRAH) to Report a Decline in Earnings: What to Look Out for

    by Zacks Equity Research

    PRA Health Sciences (PRAH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Sriparna Ghosal headshot

    3 Beaten-Down MedTech Stocks to Grab Amid Market Meltdown

    by Sriparna Ghosal

    These cheap MedTech stocks are currently flourishing on the back of a number of positive developments.